The effect of helicobacter pylori infection eradication on thrombocytopenia in patients with Liver failure.

To assess the effect of Helicobacter pylori infection eradication on thrombocytopenia in patients with cirrhosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013020112333N1

Enrollment

Registered

2013-10-14

Start date

2010-06-12

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thrombocytopenia in cirrhotic patients. Secondary thrombocytopenia

Interventions

Amoxycillin 1000 mg, omperazole 20 mg, and clarithromycine 500 mg twice daily for 2 weeks.

Treatment - Drugs

Amoxycillin 1000 mg, omperazole 20 mg, and clarithromycine 500 mg twice daily for 2 weeks

Eligibility

Sex/Gender

All

Age

17 Years to 72 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with thrombocytopenia due to cirrhosis of the liver; platelet count was less than 85,000 per micro liter; The immunoglubin anti- Helicobacter pylori antibodies were positive. Exclusion criteria at the beginning: History of previous treatment for Helicobacter pylori infection eradication; treatment with proton pump inhibitors or antibiotics in the past four weeks; History of allergy drugs for eradicate of Helicobacter pylori infection. Exclusion criteria during the study: allergy to drugs; Helicobacter pylori infection are not eradicated after treatment.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Thrombocytopenia. Timepoint: Before and 4 weeks after the end of treatment. Method of measurement: Venous blood samples.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHooman Mosannan Mozaffari

Mashhad University of Medical Sciences

MozaffariH@mums.ac.ir+98 51 1859 8818

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026